The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss: Increasing Awareness: Debunking common myths and misconceptions about HS. Building Trust: Strategies for overcoming diagnostic delays and insufficient management. Comprehensive Care: Adopting a holistic approach, including addressing common comorbidities. The Road Ahead: Exploring the future of the HS treatment landscape, including JAK inhibition.
This is the final installment of our 4-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." In this episode, "Moving into the Non-Steroidal Topical Therapy Age," we dive into the current and emerging landscape of targeted topical therapies for AD patients. Our experts review the latest clinical data, discuss how they are practically integrating these agents into their practice, and analyze the resulting impact on patient outcomes and their overall approach to AD management. Listen in as board-certified dermatologists, Mona Shahriari, MD and G. Michael Lewitt, MD discuss: Overview of targeted topical therapies, including next generation topicals Efficacy of targeted topicals compared to topical steroids Safety, limitations, and compatibility with other therapies How to integrate targeted topicals into clinical practice Pearls for treating pediatric and adult patients across the indicated age range This podcast is supported by an educational grant from Arcutis Biotherapeutics, Inc.
The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss: Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology Long-term safety of topical therapies for chronic AD Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial Shifting the paradigm of topical AD care across patient populations
This is the third part of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." This episode, "Addressing Patient Concerns Regarding Treatment of Dermatoses Using Steroids," focuses on the importance of patient education and shared decision-making. In this episode, supported by an educational grant from Arcutis, expert dermatologists Mona Shahriari, MD and Alexandra Golant, MD discuss how to effectively inform and de-escalate concerns from patients and caregivers regarding steroid treatments for atopic dermatitis. Join us as we explore: The risks and benefits of using topical steroids and non-steroidals. How to involve patients in their treatment decisions. Managing side effects from topical steroids, especially for patients with skin of color. Tips for helping patients with daily AD care. Pearls for patient education.
In the second installment of our four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," we're tackling a topic that's often misunderstood and highly challenging: Topical Steroid Withdrawal (TSW). Supported by an educational grant from Arcutis, this episode, "Topical Steroid Withdrawal – Myths vs Science," features expert dermatologists Dr Mona Shahriari, MD, and Dr Peter Lio, MD. Join us as we separate fact from fiction and dive deep into: The common pitfalls of overusing or misusing topical corticosteroids (TCS) How to recognize the telltale signs and symptoms of TSW Effective and compassionate strategies for managing TSW The key to using TCS responsibly Understanding when to pivot to targeted, non-steroidal treatments. For those interested in the science behind TSW, we've included a link to a recent publication on the disease mechanism: Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD - PubMed
This is the first episode of a four-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD," supported by an educational grant from Arcutis. In this episode, "Steroidal vs Non-Steroidal Topicals – Case by Case Discussion," expert dermatologists, Mona Shahriari, MD and James Song, MD, discuss: Appropriate use of topical corticosteroids and targeted topicals for atopic dermatitis Benefits of topical corticosteroids and remaining unmet needs How new targeted topicals fit into the atopic dermatitis toolbox and improve adherence to therapy Case-based discussion of targeted topicals for the treatment of AD.
In this episode, entitled "JAK Inhibition for Treatment of Vitiligo," expert dermatologists, Dr Andrew Alexis, MD, MPH and Dr Erik Domingues, MD, FAAD, discuss the following topics: · Changing the culture of vitiligo care · Diagnosing vitiligo and associated comorbidities · Strategies for managing vitiligo and educating patients about treatment options · Setting patient expectations for the treatment process
This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics: Mechanism of action for IL-31 inhibitor nemolizumab Clinical safety and efficacy data for nemolizumab for treatment of PN Strategies for prescribing IL-31 inhibitors in clinical practice Pearls for patient selection and addressing treatment challenges
This is the second episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, is joined by Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, as they discuss the following topics: Setting the stage for treating a patient with EB Assessing EB severity and subtype to inform treatment Expert review of the current FDA-approved treatments and Strategies to close care gaps for EB patients
This is the sixth episode of our ongoing "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Achieving More: How and When to Switch Systemic Therapies in Atopic Dermatitis?", featuring Beth Sweney, PA-C discusses the following topics: Challenges in achieving treatment targets in AD Therapeutic inertia and clinical implications of inadequate response Comparative clinical data evaluating upadacitinib and dupilumab for treatment of AD Transitioning to systemic therapies from topical agents, immunosuppressives, and biologic therapies
This is the first episode of a two-part educational series to raise awareness of epidermolysis bullosa (EB) and the latest FDA-approved treatment options for this disease. Our host, Dr. Joyce Teng, MD, PhD, Professor of Dermatology and Pediatrics at Stanford University School of Medicine in Stanford, CA, is joined by Dr. Michael Lavery, a Pediatric Dermatologist and Clinical Assistant Professor at the University of Florida in Gainesville, FL, as they discuss the following topics: Epidemiology and prevalence of EB Burden of disease and impact on patients' quality of life Gaps and challenges for patients with EB Assessing the current knowledge of clinicians and gaps in care recommendations
This podcast episode, sponsored by Leo Pharma, features LiVDerm faculty and esteemed dermatologists Dr. Christopher Bunick, MD, PhD, and Dr. Jonathan Silverberg, MD, PhD, MPH. As experts in all things concerning eczema, our faculty discuss the differentiating features and disease burden in patients suffering from chronic hand eczema (CHE) and review the current guidance for treatment, including these specific topics: Differentiating CHE from atopic dermatitis of the hands, including triggers, pathophysiology, and clinical presentation Expert guidance for accurate diagnosis and work-up of CHE patients Challenges and limitations of current therapeutic offerings The potential of a topical novel pan-JAK inhibitor for targeted treatment of CHE
This is the first episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma and hosted by prurigo nodularis (PN) expert Dr. Shawn Kwatra, MD. This episode, "Examining the Gaps and Challenges in Diagnosing and Treating Prurigo Nodularis", featuring expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, discusses the following topics: The lack of awareness and timely, correct diagnosis of PN patients Strategies for assessing patients with PN and alleviating disease symptoms and burden Examining the current expert guidance and available therapies for treating PN Looking to the future of PN diagnosis and targeted treatment
This is the second episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "New Therapies and Expert Strategies for Long-term Control", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: The pros and cons of steroid use in treating AD Targeted non-steroidal topical therapies approved by the FDA Relevant clinical efficacy and safety data for new and emerging non-steroidal topicals Recommendations for long-term symptom control in AD patients
This is the fifth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Choosing the Right Path: JAK Inhibitors or Biologics for Atopic Dermatitis?", featuring expert dermatologist Dr. Naiem Issa, MD, PhD, discusses the following topics: Mechanistic differences between JAKi and biologics for treatment of AD Clinical data supporting the safety of JAKi in head-to-head trials compared to biologics Pearls for prescribing JAKi to AD patients Strategies for choosing JAKi vs biologics based on safety and patient factors
This is the first episode of a two-part activity on "Skirting Steroids in Atopic Dermatitis", supported by an educational grant from Arcutis Biotherapeutics, Inc., and hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Dangers and Side Effects of Steroid Exposure in Treatment of AD", featuring expert dermatologist Dr. Peter Lio, MD, discusses the following topics: Side effects of topical and oral corticosteroid exposure Pearls and gaps in current guidelines for treatment of AD Identifying topical steroid withdrawal symptoms Safety and stewardship strategies for topical steroids Future of non-steroidal advanced topical therapies for AD Record Date: 8/6/2024
This is the fourth episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy", featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics: Identifying ideal candidates for oral JAK inhibitor therapy Steps to initiate therapy and onboard new patients How to manage side effects and maintain adherence to treatment Case examples and real-world data
This is the third episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "The Quest for Itch-Free, Clear Skin in Atopic Dermatitis: New Practice-Informing Evidence", featuring expert dermatologist Dr. Jonathan Silverberg, MD, PhD, MPH, discusses the following topics: Overall impact of atopic dermatitis on patients' quality of life Overview of the role of various existing treatments for AD and expert guidelines Discussion of LEVEL UP clinical trial data comparing upadacitinib and dupilumab Defining treatment success and best practices for treatment selection www.livderm.org
This special podcast episode, developed in collaboration with UCB, features LiVDerm faculty and esteemed dermatologists Dr. Jennifer Hsiao, MD, and Dr. Hadar Lev-Tov, MD. As experts in all things hidradenitis suppurativa (HS), our faculty discuss the need for early and accurate diagnosis and assessment of patients with HS in order to prescribe treatment at the best time to achieve disease control, including the following topics: Key challenges in treating patients with moderate-to-severe HS The role of targeted, systemic therapies in HS management Defining "moderate" disease and strategies for severity assessment Defining window of opportunity and strategies for advanced treatment of HS Defining and assessing treatment response and success with targeted therapies
This is the second episode of our new "Program on JAK Inhibitors for Atopic Dermatitis" series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, "JAK Inhibitors in Action: Effectiveness in Atopic Dermatitis", featuring expert dermatologist Dr. James Song, MD, discusses the following topics: Short- and long-term efficacy and safety data for JAK inhibitor therapies New topline data from the LEVEL UP trial studying upadacitinib in comparison to dupilumab for the treatment of patients aged 12 years and older with moderate-to-severe AD Head-to-head studies and real-world evidence evaluating JAK inhibitor therapies Emerging clinical developments and what's coming next in JAK inhibitor research